Advertisement

Documenta Ophthalmologica

, Volume 119, Issue 1, pp 29–36 | Cite as

Transitions of multifocal electroretinography following combined intravitreal bevacizumab and photodynamic therapy for polypoidal choroidal vasculopathy

  • Chengguo Zuo
  • Feng Wen
  • Jiaqing Li
  • Yan Liu
  • Meng Li
Original Research Article

Abstract

To investigate the changes in the multifocal electroretinography (ERG) after combined intravitreal bevacizumab and photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV) patients. Thirteen eyes of 13 patients were included in the study. The latencies and average response densities of all the six ring retinal regions were measured and compared before treatment and 1, 3, and 6 months after treatment. The latencies of the N1 and P1 waves in all the six rings remained unchanged compared with pre-treatment. Significant increase of average response densities of both P1 in ring 1 (= 0.023) and N1, P1 in ring 2 (P = 0.028 and 0.046, respectively) were detected at 3 months post-treatment. The increase of P1 amplitude densities in ring 1 (P = 0.015) and N1, P1 amplitude densities in ring 2 (= 0.031 and 0.034, respectively) were also significant at 6 months post-treatment. In conclusion, combined intravitreal bevacizumab and PDT is associated with an increase of multifocal ERG centrally in PCV patients.

Keywords

Polypoidal choroidal vasculopathy Photodynamic therapy Bevacizumab Multifocal electroretinography 

Notes

Acknowledgments

This study was supported by the National Basic Research Program of China (grant no. 2007CB512206).

References

  1. 1.
    Yannuzzi LA, Ciardella A, Spaide RF, Rabb M, Freund KB, Orlock DA (1997) The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy. Arch Ophthalmol 115:478–485PubMedGoogle Scholar
  2. 2.
    Yannuzzi LA, Wong DW, Sforzolini BS et al (1999) Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration. Arch Ophthalmol 117:1503–1510PubMedGoogle Scholar
  3. 3.
    Lafaut BA, Leys AM, Snyers B, Rasquin F, De Laey JJ (2000) Polypoidal choroidal vasculopathy in Caucasians. Graefes Arch Clin Exp Ophthalmol 238:752–759. doi: 10.1007/s004170000180 PubMedCrossRefGoogle Scholar
  4. 4.
    Yannuzzi LA, Sorenson J, Spaide RF, Lipson B (1990) Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 10:1–8. doi: 10.1097/00006982-199001010-00001 PubMedCrossRefGoogle Scholar
  5. 5.
    Ciardella AP, Donsoff IM, Huang SJ, Costa DL, Yannuzzi LA (2004) Polypoidal choroidal vasculopathy. Surv Ophthalmol 49:25–37. doi: 10.1016/j.survophthal.2003.10.007 PubMedCrossRefGoogle Scholar
  6. 6.
    Ziemssen F, Luke M, Bartz-Schmidt KU, Gelisken F (2008) Time-dependent effects on contrast sensitivity, near and distance acuity: difference in functional parameters? (Prospective, randomized pilot trial of photodynamic therapy versus full macular translocation). Graefes Arch Clin Exp Ophthalmol 246:653–659. doi: 10.1007/s00417-007-0726-y PubMedCrossRefGoogle Scholar
  7. 7.
    Wakabayashi T, Gomi F, Sawa M, Tsujikawa M, Tano Y (2008) Marked vascular changes of polypoidal choroidal vasculopathy after photodynamic therapy. Br J Ophthalmol 92:936–940. doi: 10.1136/bjo.2007.132357 PubMedCrossRefGoogle Scholar
  8. 8.
    Lee WK, Lee PY, Lee SK (2008) Photodynamic therapy for polypoidal choroidal vasculopathy: vaso-occlusive effect on the branching vascular network and origin of recurrence. Jpn J Ophthalmol 52:108–115. doi: 10.1007/s10384-007-0501-y PubMedCrossRefGoogle Scholar
  9. 9.
    Kurashige Y, Otani A, Sasahara M et al (2008) Two-year results of photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 146:513–519. doi: 10.1016/j.ajo.2008.05.025 PubMedCrossRefGoogle Scholar
  10. 10.
    Akaza E, Mori R, Yuzawa M (2008) Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy. Retina 28:717–722. doi: 10.1097/IAE.0b013e31816577cb PubMedCrossRefGoogle Scholar
  11. 11.
    Tong JP, Chan WM, Liu DT et al (2006) Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol 141:456–462. doi: 10.1016/j.ajo.2005.10.012 PubMedCrossRefGoogle Scholar
  12. 12.
    Matsuoka M, Ogata N, Otsuji T, Nishimura T, Takahashi K, Matsumura M (2004) Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy. Br J Ophthalmol 88:809–815. doi: 10.1136/bjo.2003.032466 PubMedCrossRefGoogle Scholar
  13. 13.
    Wakusawa R, Abe T, Sato H et al (2008) Expression of vasohibin, an antiangiogenic factor, in human choroidal neovascular membranes. Am J Ophthalmol 146:235–243. doi: 10.1016/j.ajo.2008.03.019 PubMedCrossRefGoogle Scholar
  14. 14.
    Gomi F, Sawa M, Sakaguchi H et al (2008) Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol 92:70–73. doi: 10.1136/bjo.2007.122283 PubMedCrossRefGoogle Scholar
  15. 15.
    Lai TY, Chan WM, Liu DT, Luk FO, Lam DS (2008) Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Br J Ophthalmol 92:661–666. doi: 10.1136/bjo.2007.135103 PubMedCrossRefGoogle Scholar
  16. 16.
    Lee SY, Kim JG, Joe SG, Chung H, Yoon YH (2008) The therapeutic effects of bevacizumab in patients with polypoidal choroidal vasculopathy. Korean J Ophthalmol 22:92–99. doi: 10.3341/kjo.2008.22.2.92 PubMedCrossRefGoogle Scholar
  17. 17.
    Yamashiro K, Tsujikawa A, Nishida A, Kurimoto Y (2007) Determinants of patient satisfaction with photodynamic therapy for neovascular age-related macular degeneration or polypoidal choroidal vasculopathy. Jpn J Ophthalmol 51:368–374. doi: 10.1007/s10384-007-0465-y PubMedCrossRefGoogle Scholar
  18. 18.
    Mauget-Faysse M, Quaranta-El Maftouhi M, De La Marnierre E, Leys A (2006) Photodynamic therapy with verteporfin in the treatment of exudative idiopathic polypoidal choroidal vasculopathy. Eur J Ophthalmol 16:695–704PubMedGoogle Scholar
  19. 19.
    Lai TY, Chan WM, Lam DS (2004) Transient reduction in retinal function revealed by multifocal electroretinogram after photodynamic therapy. Am J Ophthalmol 137:826–833. doi: 10.1016/j.ajo.2003.11.079 PubMedCrossRefGoogle Scholar
  20. 20.
    Imai H, Honda S, Nakanishi Y, Yamamoto H, Tsukahara Y, Negi A (2006) Different transitions of multifocal electroretinogram recordings between patients with age-related macular degeneration and polypoidal choroidal vasculopathy after photodynamic therapy. Br J Ophthalmol 90:1524–1530. doi: 10.1136/bjo.2006.092783 PubMedCrossRefGoogle Scholar
  21. 21.
    Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group (1999) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials—TAP report. Arch Ophthalmol 117:1329–1345Google Scholar
  22. 22.
    Bressler NM (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials: TAP report 2. Arch Ophthalmol 119:198–207PubMedGoogle Scholar
  23. 23.
    Hood DC, Bach M, Brigell M et al (2008) ISCEV guidelines for clinical multifocal electroretinography (2007 edition). Doc Ophthalmol 116:1–11. doi: 10.1007/s10633-007-9089-2 PubMedCrossRefGoogle Scholar
  24. 24.
    Chan WM, Liu DT, Lai TY, Li H, Tong JP, Lam DS (2005) Extensive submacular haemorrhage in polypoidal choroidal vasculopathy managed by sequential gas displacement and photodynamic therapy: a pilot study of one-year follow up. Clin Exp Ophthalmol 33:611–618. doi: 10.1111/j.1442-9071.2005.01105.x CrossRefGoogle Scholar
  25. 25.
    Silva RM, Figueira J, Cachulo ML, Duarte L, Faria de Abreu JR, Cunha-Vaz JG (2005) Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin. Graefes Arch Clin Exp Ophthalmol 243:973–979. doi: 10.1007/s00417-005-1139-4 PubMedCrossRefGoogle Scholar
  26. 26.
    Imai H, Honda S, Nakanishi Y, Yamamoto H, Tsukahara Y, Negi A (2006) Different transitions of multifocal electroretinogram recordings between patients with age-related macular degeneration and polypoidal choroidal vasculopathy after photodynamic therapy. Br J Ophthalmol 90:1524–1530. doi: 10.1136/bjo.2006.092783 PubMedCrossRefGoogle Scholar
  27. 27.
    Eandi CM, Ober MD, Freund KB, Slakter JS, Yannuzzi LA (2007) Selective photodynamic therapy for neovascular age-related macular degeneration with polypoidal choroidal neovascularization. Retina 27:825–831PubMedCrossRefGoogle Scholar
  28. 28.
    Gomi F, Ohji M, Sayanagi K et al (2008) One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology 115:141–146. doi: 10.1016/j.ophtha.2007.02.031 PubMedCrossRefGoogle Scholar
  29. 29.
    Sayanagi K, Gomi F, Sawa M, Ohji M, Tano Y (2007) Long-term follow-up of polypoidal choroidal vasculopathy after photodynamic therapy with verteporfin. Graefes Arch Clin Exp Ophthalmol 245:1569–1571. doi: 10.1007/s00417-007-0582-9 PubMedCrossRefGoogle Scholar
  30. 30.
    Sutter EE, Tran D (1992) The field topography of ERG components in man—I. The photopic luminance response. Vis Res 32:433–446. doi: 10.1016/0042-6989(92)90235-B PubMedCrossRefGoogle Scholar
  31. 31.
    Feigl B, Lovie-Kitchin J, Brown B (2005) Objective functional assessment of age-related maculopathy: a special application for the multifocal electroretinogram. Clin Exp Optom 88:304–312PubMedCrossRefGoogle Scholar
  32. 32.
    Moschos MM, Brouzas D, Apostolopoulos M, Koutsandrea C, Loukianou E, Moschos M (2007) Intravitreal use of bevacizumab (Avastin) for choroidal neovascularization due to ARMD: a preliminary multifocal-ERG and OCT study. Multifocal-ERG after use of bevacizumab in ARMD. Doc Ophthalmol 114:37–44. doi: 10.1007/s10633-006-9036-7 PubMedCrossRefGoogle Scholar
  33. 33.
    Shetty R, Pai SA, Vincent A et al (2008) Electrophysiological and structural assessment of the central retina following intravitreal injection of bevacizumab for treatment of macular edema. Doc Ophthalmol 116:129–135. doi: 10.1007/s10633-007-9090-9 PubMedCrossRefGoogle Scholar
  34. 34.
    Jiang L, Jin C, Wen F, Huang S, Wu D, Wu L (2003) The changes of multifocal electroretinography in the early stage of photodynamic therapy for choroidal neovascularization. Doc Ophthalmol 107:165–170. doi: 10.1023/A:1026215221569 PubMedCrossRefGoogle Scholar
  35. 35.
    Bellmann C, Neveu MM, Scholl HP et al (2004) Localized retinal electrophysiological and fundus autofluorescence imaging abnormalities in maternal inherited diabetes and deafness. Invest Ophthalmol Vis Sci 45:2355–2360. doi: 10.1167/iovs.03-1090 PubMedCrossRefGoogle Scholar
  36. 36.
    Tsunoda K, Oguchi Y, Hanazono G, Tanifuji M (2004) Mapping cone- and rod-induced retinal responsiveness in macaque retina by optical imaging. Invest Ophthalmol Vis Sci 45:3820–3826. doi: 10.1167/iovs.04-0394 PubMedCrossRefGoogle Scholar
  37. 37.
    Hood DC, Frishman LJ, Saszik S, Viswanathan S (2002) Retinal origins of the primate multifocal ERG: implications for the human response. Invest Ophthalmol Vis Sci 43:1673–1685PubMedGoogle Scholar
  38. 38.
    Meyer CH, Lapolice DJ, Fekrat S (2005) Functional changes after photodynamic therapy with verteporfin. Am J Ophthalmol 139:214–215. doi: 10.1016/j.ajo.2004.07.034 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Chengguo Zuo
    • 1
  • Feng Wen
    • 1
  • Jiaqing Li
    • 1
  • Yan Liu
    • 1
  • Meng Li
    • 1
  1. 1.State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic CenterSun Yat-Sen UniversityGuangzhouChina

Personalised recommendations